Monday, 01 June 2020

Amgen, Syapse enter precision medicine collaboration in oncology

03 May 2019 | News

Supports providers with advanced insight tools and research opportunities

image credit-

image credit-

Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, today announced a precision medicine collaboration in oncology.

Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology. This effort will identify existing patients within the Syapse Learning Health Network that could be eligible for Amgen-sponsored clinical trials and seek to bring these trials to community health system sites.

The companies will create opportunities for physicians and researchers within the Syapse Network to gain access to analytics, real-world evidence-based insights, and collaborative research opportunities. Amgen will have access to real-world evidence for potential use in regulatory filings in support of certain agreed upon development candidates in oncology. Amgen will also work with Syapse to develop real-world evidence standards to support the acceleration of therapies to market.   


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account